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ABSTRACT
Antiblastic drugs have a high number of potential side-effects. Paradoxically, 
according to the National Network of Pharmacovigilance, the number of reported 
adverse reactions to these agents is proportionally lower than that registered for non 
antiblastic drugs. Critical phenomena such as treatment interruptions and significant 
dose reductions within the first two months of use may be indicators of adverse 
drug reactions. The aim of the present study was to increase our knowledge of 
pharmacovigilance to facilitate the actions taken to improve the risk-benefit profile of 
cancer drugs and, consequently, their safety. This retrospective observational survey 
was carried out on prescriptions from 1st January 2012 to 31st December 2012.Dose 
reductions of more than 10% during the first 90 days of therapy were considered as a 
surrogate indicator of an adverse reaction. Dose interruptions during the first 60 days 
of therapy were taken into consideration. Of the12,472 patients 1,248 underwent a 
dose reduction. The drugs that most often required a dose reduction were paclitaxel 
and oxaliplatin (17.4% and 17.3%, respectively), docetaxel (14.8%), carboplatin 
(15%), fluorouracil (10.7%) and, among oral medications, capecitabine (6.9%). Of 
the 1896 patients treated with the same drugs, 9.7% interrupted treatment. Patients 
required a lower dose reduction than that reported by other authors. Around 15% 
of cases underwent a 30% dose reduction within three months of starting therapy, 
indicating a possible adverse reaction. Constant monitoring of dose prescription 
and continuous training of medical and nursing staff are clearly needed to increase 
awareness of the importance of reporting adverse events.
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INTRODUCTION
Pharmacovigilance has been defined by the World 
Health Organization (WHO) as “the science and activities 
relating to the detection, assessment, understanding and 
prevention of adverse effects or any other possible drug-
related problems” [1]. The correct Adverse drug reaction 
definition (ADRs) is : reaction noxious and unintended, 
to medicinal products used at doses normally used in man 
for the prophylaxis, diagnosis or treatment, correction or 
modification of physiological functions. Adverse events 
are unwanted and usually harmful outcomes. The event 
may or may not be related to the treatment, and is not the 
same as a side effect or an adverse reaction because it is 
not always clear whether the drug has caused the event.
In a meta-analysis conducted from 1966 to 1996 on 
a sample of hospitalized patients, Lazarou and colleagues 
reported that the overall incidence of serious ADRs was 
6.7% (95% confidence interval [CI] 5.2%-8.2%) and that 
the incidence of fatal ADRs was 0.32% (95% CI 0.23%-
0.41%) [2]. They estimated that, in 1994, 2,216,000 
hospitalized patients had serious ADRs and 106,000 had 
fatal ADRs, making these reactions between the fourth and 
sixth leading causes of death.
Antineoplastic agents have a potentially high 
number of side-effects. The overall safety profile of cancer 
drugs is not known, yet this is an element that allows us to 
monitor the patient’s quality of life. For this reason, it is 
of vital importance to report adverse events, even if these 
are not serious and have already been documented. A good 
internal reporting system ensures that all parties involved 
responsible are aware of major hazards. Reporting ADRs 
is also essential to monitor the progress made in error 
prevention [3]. 
In 2012, around 70,150 expedited adverse reaction 
reports were received and processed each month and 
subsequently made available for signal detection and 
data analysis by the European Medicines Agency (EMA) 
and the medicine regulatory authorities of Member 
States. Of these, 15% were reports on cancer drugs [4]. 
Consequently, an Italian study on ADR reporting was 
performed by the National Network of Pharmacovigilance 
[5] and data on cancer-related ADRs reported in 2011 
were extrapolated. 21,473 ADRs equivalent to a signaling 
rate of 356 reportsper million inhabitants were received 
by the Italian National Network of Pharmacovigilance, 
and a total of 300 reports per one million people in the 
population was reached and exceeded, 300 being the figure 
defined by WHO as the gold standard for an efficient 
pharmacovigilance system.
European pharmacovigilance legislation also 
considers a lack of treatment efficacy and medication 
errors as adverse reactions. Such events are not intrinsic to 
the patient or the drug, but are related to the management 
of the correlated processes, which can influence the risk-
benefit profile. It is clear that such phenomena in a cancer 
setting must be closely monitored. It is essential to keep 
track of critical events such as treatment interruptions and 
significant dose reductions that occur within the first two 
months of treatment.
The aim of the present study were also to identify 
and report suspected adverse durg reactions and increase 
communication between pharmacist and oncologist 
for proper overall management of the drug, since the 
pharmacovigilance system.
RESULTS
Of the12,472 patients who received one of the study 
drugs from 1st January 2012 to 31st March 2013, 11,596 
were treated intravenously and 876 orally. 1197 (10.3%) 
patients in the former group underwent a dose reduction 
during the first 3months of treatment compared to 51 
(5.8%) the latter group. Table 1 shows the percentage of 
patients who required a dose reduction with respect to the 
entire case series. 
The most frequent dose reductions in intravenous 
drugs were made in paclitaxeland oxaliplatin (17.4%and 
17.3% of patients, respectively), followed by docetaxel 
(14.8 %), carboplatin (15%) and fluorouracil (10.7%). 
Among orally administered drugs, capecitabine showed 
the highest percentage of dose reduction (6.9%). No dose 
reductions were required in the 59 patients treated with 
lenalidomide.
Of the1896 patients who received one of the study 
drugs from 1st January 2012 to 28st February 2012,1575 
were treated intravenously and 321 orally. Treatment 
interruption due to adverse drug reactions (ADRs) 
occurred in133 (8.4%) patients of the intravenous group 
and 51 (15.9%) of the oral group. The highest number of 
ADRs leading to treatment discontinuation were registered 
for ifosfamide (12 ADRs in 35 patients) followed by 
doxorubicin (23ADRs in 164 patients), carboplatin (32 
ADRs in 300 patients) and paclitacxel (14ADRs in 147 
patients) (Table 2).
8.7% of patients discontinued treatment during 
adjuvant therapy, 23.7% of whom during first-line 
therapy, 13.5% during second-line therapy, 20% during 
third-line therapy, 11.1% during fourth-line therapy, and 
33.3% during fifth-line therapy. Intravenous medication 
was discontinued in 8.4% of cases (133/1575), while oral 
medications were discontinued in 15.9% of cases (51/321).
In dose reduction analysis the percentage of patients 
treated by intravenous drug was 92.7% and 7,3% with 
oral drugs. In discontinuation analysis the percentage of 
patients treated by intravenous drug was 83% and 17% 
with oral drugs. 
A total of 242 ADRs were reported by the 7 centers 
in the National Network of Pharmacovigilance (RNF), 
representing an increase of 52% compared with the 
previous year. The main drugs involved were paclitaxel, 
oxaliplatin, fluorouracil, carboplatin, and bevacizumab. 
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84% of reported events were considered non-serious and 
16% serious. 
DISCUSSION
The aim of pharmacovigilance is to assess the post-
marketing safety of drugs. In oncology, adverse drug 
reactions are still underreported. Ten percent of patients 
in the underwent dose reduction and 9.7% of patients 
interrupted treatment. The reduction of intravenously 
drug (10.3%) was almost twofold that oral target (5.8%). 
This is because, according to our data, the targeted therapy 
drugs are reduced to a smaller percentage compared 
to the data obtained from the studies. For example, in a 
study of 84 non-small-cell lung cancer patients treated 
with erlotinib, the drug was reduced in 21% of cases 
experiencing grade 3 or 4 adverse events [6].We treated 
108 patients with erlotinib but only experienced three 
dose reductions amounting to 2.8% of receiving this drug. 
Sorafenib, another oral drug, was reduced in 4.3% of our 
patients, whereas the SHARP trial [7-8] reported that 
9.4% of patients experienced toxicity ≥ grade 3 protocol 
amendment. 
In our study, 13.5% of patients who reduced the dose 
of chemotherapy within three months of starting treatment 
underwent a reduction of more than 30%. Some drugs, e.g. 
paclitaxel, were reduced in 21.9% of patients with a higher 
dosage of 30%, while anthracyclines were reduced in 20% 
of cases with a higher dosage of 30%. As these reductions 
occurred in the first three months of treatment, they could 
probably be linked to suspected adverse reactions that are 
regarded as ADRs.
An interesting issue that could be evaluated in 
another study is whether PFS and OS was affected in 
patients who underwent a dose reduction of more than 
30%. 
Our study highlights a very interesting phenomenon 
regarding the difference between the interruption of 5-FU 
and capecitabine. We observed that patients treated with 
capecitabine interrupted treatment much more frequently 
than those receiving 5-FU. In fact, capecitabine was 
discontinued in 17.1% of cases compared to only 6.3% of 
Table 1: Percentage of dose reductions
Intravenous drugs
Active
No. of patients 
undergoing 
treatment
No. of patients 
with dose 
reduction
% Rate of reduction40%-50%≤ 10%-20%≤ 20%-30%≤ 30%-40%≤
Paclitaxel 1208 210 17.4 17 68 96 29
Oxaliplatin 1297 224 17.3 10 95 105 14
Carboplatin 1690 255 15.0 8 160 69 18
Docetaxel 995 147 14.8 3 77 49 18
Fluorouracil 2351 252 10.7 13 104 121 14
Ifosfamide 231 11 4.8 0 5 4 2
Anthracycline 2148 75 3.5 7 51 9 8
Pemetrexed 392 10 2.6 0 10 0 0
Rituximab 1284 13 1.0 0 12 0 1
Total 11596 1197 10.3 58 582 453 104
Oral drugs
Active
No. of patients 
undergoing 
treatment
No. of patients 
with dose 
reduction
% Rate of reduction
40%-50%≤
10%-20%≤ 20%-30%≤ 30%-40%≤
Capecitabine 662 46 6.9 3 23 17 4
Erlotinib 108 3 2.8 0 0 0 3
Sorafenib 47 2 4.3 1 1 0 0
Lenalidomide 59 0 0.0 0 0 0 0
Total 876 51 5.80 4 24 17 7
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patients receiving 5-FU. In fact, several studies comparing 
capecitabine + oxaliplatin and 5-FU + oxaliplatin 
concluded that the two treatments are comparable in terms 
of both efficacy and toxicity [9-13].Such findings highlight 
the difference between published data and our post-
marketing data, which confirmed that capecitabine was 
interrupted more frequently because of severer toxicity.
Ifosfamide was the most frequently reduced drug, 
one in three patients stopping chemotherapy due to an 
adverse event. A decidedly different issue (problem) 
is that of nephrotoxicity during treatment. It has been 
reported to be responsible for clinical nephrotoxicity in 
around 30% of patients, although about 90% of cases also 
manifest subclinical tubular toxicity with glycosuria and 
β2-microglobulinuria [14]. In our study, the interruption 
of ifosfamide was due to the development of renal failure. 
In routine clinical practice, dose reduction or 
treatment interruption is sometimes necessary when the 
risk-benefit ratio of the drug is not worth for the patient. 
Such action may also be taken in the event of unexpected 
side-effects or complications/reactions that have not as yet 
been identified as a side-effect of the drug in question. This 
may happen because phase I, II and III studies generally 
analyze no more than 2000 patients. This only allows 
us to recognize common side effects, while uncommon 
side effects are often not recognized in the early stages 
of experimentation. Uncommon side-effects are those 
reported in less than 1 case per thousand population 
and it is the task of pharmacovigilance to identify them. 
Although rare, the clinician must nevertheless be aware 
of these events. In addition, patients enrolled onto 
clinical trials are selected and do not reflect the patient 
population. Generally, in the studies, patients are more 
selected. Elderly patients and patients affected by heart 
disease are excluded from studies. This patients are, 
however, normally present in clinical practice. Therefore 
pharmacovigilance system is very important for report any 
toxicities in all categories of patients. 
The main limitation of our study was the lack 
of clinical data available, which led to difficulties in 
analyzing the types of patients involved in the study. It 
was not therefore possible to identify the clinical features 
that may have contributed to the onset of the adverse 
reactions studied.
In conclusion, this study shows that post-marketing 
drug studies should be conducted in a more in-depth, 
systematic way, thus allowing us to evaluate both the 
effectiveness and the tolerance levels of the treatments. 
A program of active pharmacovigilance such as the one 
we have created at our institute is essential if the objective 
is to continuously monitor cancer drugs. In our study, by 
identifying patients who discontinued treatment we were 
able to discern adverse reactions which were then included 
in the National Network of Pharmacovigilance. A program 
Table 2: Drugs with the highest percentage of clinical reaction leading to discontinuation
Intravenous drugs No. of patients undergoing treatment No. of patients with clinical events %
Ifosfamide 35 12 34.3
Doxorubicin 164 23 14.0
Carboplatin 300 32 10.7
Paclitaxel 147 14 9.5
Epirubicin 22 2 9.0
Docetaxel 133 12 9.0
Oxaliplatin 139 9 6.8
Fluorouracil 302 19 6.3
Pemetrexed 41 2 4.9
Rituximab 292 8 2.7
Total 1575 133 8.4
Oral drugs
Lenalidomide 28 7 25.0
Capecitabine 240 41 17.1
Sorafenib 27 3 11.1
Erlotinib 26 0 0.0
Total 321 51 15.9
Total intravenous 
+ oral drugs 1896 184 9.0
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of prospective, active pharmacovigilance will provide us 
with the opportunity of identifying and reporting more 
significant adverse events.
MATERIALS AND METHODS
This retrospective observational study was designed 
to monitor critical phenomena, including dose reduction 
and treatment interruption, as potential indicators of 
ADRs. The following centers were involved in the study: 
IRST IRCCS, Meldola, Ravenna, Rimini and Reggio 
Emilia Hospitals, and the University Hospitals of Bologna, 
Ferrara and Parma. All consecutive cancer patients treated 
with non-experimental cancer drugs in adjuvant, locally 
advanced and metastatic settings were included in the 
study. Dose reductions were taken into consideration 
from 1st January 2012- 31st March 2013. Treatment 
discontinuation was evaluated from 1st January 2012 to 
28st February 2012 as this was considered long enough to 
highlight any interruptions caused by adverse reactions. 
Exclusion criteria were as follows: treatment regimens 
lasting ≤ 60 day; treatment discontinuation because of 
planned radiotherapy; non attendance for treatment; and 
treatment discontinuation due to surgery.
Intravenous (5-fluorouracil, oxaliplatin, carboplatin, 
docetaxel, paclitaxel, rituximab, pemetrexed, doxorubicin, 
ifosfamide) and oral (erlotinib, sorafenib, lenalidomide, 
capecitabine) drugs were considered for the study. 
All data were retrieved from the institute’s 
prescription pharmacy database (Log80).
Although no formal statistical hypotheses were 
formulated due to the explorative nature of this study, 
appropriate descriptive statistics were performed.
We analyzed the frequency of >10% dose reduction 
during the first 90 days of treatment, calculated on the basis 
of the actual dose administered to the patient rather than 
the dose prescribed according to the regimen. Ninety days 
were calculated as an appropriate length of time in which 
an adverse reaction might occur. Treatment interruption 
was calculated on the basis of the disappearance of the 
patient’s name from the pharmacy database within 60 days 
of the first prescription.
We used a regional administrative database. The 
study database was anonymized by deleting the identity 
of the patients and other sensitive information and by 
assigning a unique numerical code to each individual. 
When anonymized administrative data are used for 
healthcare planning, studies are exempt from formal ethics 
review and specific written consent is not required to use 
patient information stored in hospital databases.
All the authors of this manuscript are affiliated with 
the centers that participated in the multicentric study. They 
received the anonymous data from electronic archives. 
None of the authors had direct contact with patients at any 
time during the study. 
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